Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in Central Nervous System disorders and other disorders. Co.'s primary programs are SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia. SLS-005 for the potential treatment of Sanfilippo Syndrome requires additional natural history data, which is being considered. Co. is also developing several preclinical programs, including SLS-004 and SLS-007, for the potential treatment of Parkinson's Disease.
|
Free SEEL Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (3.33 out of 4) 46th percentile
(ranked lower than approx. 54% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |